Why Sleep Apnea Is Often Mistaken for Multiple Sclerosis Fatigue and How to Tell Them Apart
Telling sleep apnea and multiple sclerosis fatigue apart before you accept another explanation
Two conditions produce the same exhaustion, but only one of them shows up on an overnight recording you can arrange this month.
Why sleep apnea and multiple sclerosis fatigue are so easy to confuse
Sleep apnea and multiple sclerosis fatigue produce the same daily complaint from two completely different mechanisms. MS fatigue is a neurological energy failure. Sleep apnea is repeated interruption of breathing that fragments the night and strips sleep of its restorative stages.
The mix-up has a real cost, because only one of the two can be measured overnight and treated within weeks. A 2024 meta-analysis in Frontiers in Neurology pooled 30 studies and 6,447 people with MS and found obstructive sleep apnea-hypopnea syndrome (OSAHS) in 36% when polysomnography was used. Yet the classic signs of daytime drowsiness are usually filed under the MS diagnosis and never investigated.
That same 2024 analysis found OSAHS was 1.67 times more common in people with MS than in controls (OR 1.67; 95% CI 1.03-2.72; p=0.04). Their apnea-hypopnea index (AHI) was higher too, at 17.02 versus 9.16 in healthy controls (p=0.001).
Fatigue, meanwhile, is close to universal. A separate 2024 systematic review in Frontiers in Neurology covering 69 studies and 44,468 patients put pooled MS fatigue at 59.1%, and the WHO European Region had the highest regional figure at 61.2%.
Fatigue prevalence also tracked the MS phenotype in that 2024 review: 74.4% in secondary progressive MS, 64.3% in primary progressive MS and 54.7% in relapsing-remitting MS. Sleep-disordered breathing (SDB) can sit underneath any of them.
- Both problems are common in MS, so having one never rules out the other.
- Sleep apnea is measurable and treatable; primary MS fatigue currently is not.
- European MS populations report the highest fatigue prevalence of any WHO region (Frontiers in Neurology, 2024).
How to tell sleep apnea and multiple sclerosis fatigue apart at home
The most useful distinction is fatigue versus sleepiness. Fatigue is an energy and effort failure that persists no matter how well you slept. Sleepiness is the pressure to fall asleep, and it shows itself when you doze off without meaning to.
Clinicians describe fatigue without sleepiness as common in MS, while sleepiness without fatigue is rare. So the useful question is not whether you feel tired. It is whether your eyes close on their own.
| What you notice | Primary MS fatigue | Sleep apnea sleepiness |
|---|---|---|
| Core sensation | Energy collapses and the body refuses the effort | Difficulty staying awake; eyelids close by themselves |
| After a genuinely full night | Usually unchanged | Often noticeably better |
| Unintentional dozing | Not typical | Typical, while reading, travelling or watching TV |
| Overnight clues | Nocturia, nocturnal spasticity, restless legs syndrome, insomnia | Snoring, gasping, breathing pauses seen by a partner |
| Morning signature | No consistent morning pattern described | Morning headache and waking unrefreshed |
| How it is measured | Questionnaires such as the Fatigue Severity Scale (FSS) or Modified Fatigue Impact Scale (MFIS) | An overnight breathing recording that produces an AHI |
Objective data supports the split. Among 195 people with MS studied by Braley and colleagues in the Journal of Clinical Sleep Medicine (2014), FSS scores were markedly higher in those at elevated OSA risk than in those who were not, at 5.1 versus 4.0 (p<0.0001).
A small Croatian MS cohort of 28 patients, published in Acta Clinica Croatica (2022), found excessive daytime sleepiness (EDS, or somnolence diurne excessive) was significantly associated with fatigue (p=0.015) and with depressive symptoms (p=0.004). That supports the idea that part of this burden may come from an underlying sleep disorder rather than from MS pathology itself.
- Ask whether you doze off unintentionally, not simply whether you feel tired.
- Improvement after one unusually good night points towards a sleep problem.
- Higher FSS scores were linked to elevated OSA risk in MS (Journal of Clinical Sleep Medicine, 2014).
Why a low STOP-BANG score does not clear you
Screening questionnaires behave differently in multiple sclerosis than in the general population. They were built around snoring, body size, blood pressure and observed apneas, and they miss people whose profile does not match that template.
In 200 people with MS who underwent polysomnography, reported in Multiple Sclerosis Journal (2021), 78% were diagnosed with obstructive sleep apnea. The STOP-BANG questionnaire at a threshold of 3 or more reached 87% sensitivity but only 43% specificity for moderate-to-severe disease (AHI 15 or above), with a negative predictive value of just 40% for mild OSA (AHI 5 or above).
In plain terms, a low-risk STOP-BANG result in MS is closer to a coin toss than to an all-clear. The 2024 Frontiers in Neurology meta-analysis showed the same pattern at population level, with prevalence of 26% by STOP-BANG and 30% by the Berlin Questionnaire against 36% by polysomnography.
- STOP-BANG catches most moderate-to-severe cases but flags many false positives (Multiple Sclerosis Journal, 2021).
- Its negative predictive value for mild OSA in MS was only 40% in that cohort.
- Questionnaire-based prevalence sat well below polysomnography-based prevalence (Frontiers in Neurology, 2024).
Obstructive and central sleep apnea are not the same problem
Obstructive sleep apnea is a mechanical event. The upper airway narrows or collapses while the chest and diaphragm keep working, so effort continues and snoring is often audible.
Central sleep apnea is a signalling event. The drive to breathe briefly stops, so there is no effort and frequently no snoring at all. Brainstem demyelinating lesions are the classic reason central events are discussed in MS, and the literature links demyelination affecting respiratory control to sleep-disordered breathing risk.
The distinction changes what happens next. A report showing predominantly central events belongs with a sleep physician and your neurology team, not with any over-the-counter device. It is also why a quiet night is never a reason to skip testing when you have MS.
- Absence of snoring does not exclude sleep apnea, particularly central events.
- Obstructive and central apnea need different specialists and different treatment.
- Only a recording that measures airflow and effort can separate the two.
What a sleep test actually involves in France, the UK and Germany
In all three countries the first-line test is normally done in your own bed, not in a laboratory. That matters if transfers, mobility aids, catheter care or a carer's schedule make an overnight hospital stay feel impossible.
| Country | First-line test | Who arranges it | Escalation to a laboratory |
|---|---|---|---|
| France | Polygraphie ventilatoire nocturne at home, recording ECG, respiratory movements, airflow and blood oxygen saturation over at least 6 hours (Ameli) | The prescribing physician | Ameli describes full polysomnography as a complex exam that is not systematically prescribed |
| United Kingdom | A home sleep apnoea test (HSAT), a device worn overnight measuring breathing and heartbeat (NHS) | Your GP refers to a specialist sleep clinic | A clinic stay is only sometimes needed |
| Germany | Ambulante Polygraphie as screening | GP, HNO (ENT) or pulmonology specialist | Polysomnographie in a certified Schlaflabor when findings warrant it |
Nothing is injected and nothing hurts. You wear sensors, you sleep, you return the kit. For the full picture of what each option records, read our guide to the home sleep test versus a lab sleep study before your appointment.
Search terms differ across Europe. French readers search SAOS or SAHOS and sclérose en plaques (SEP), German readers search Schlafapnoe and Multiple Sklerose, and UK readers spell it apnoea. NICE guideline NG202 covers OSAHS in people over 16 and supports both the ESS and STOP-BANG for structured assessment.
- France, the UK and Germany all start with a take-home respiratory recording.
- German pathways escalate to a certified Schlaflabor, whose standards are set by the DGSM.
- A laboratory night is the exception, so mobility concerns need not delay testing.
Your AHI band decides what your health system will fund
The apnea-hypopnea index counts breathing events per hour of sleep, and the band it falls into drives the treatment offer. Reports may also show an oxygen desaturation index (ODI) alongside it. Crucially, the bands are not identical across Europe.
Assurance Maladie (Ameli) sets the French bands as IAH 5 to 15 légère, 16 to 30 modérée and above 30 severe. The NHS bands OSA as mild at AHI 5 to 14, moderate at 15 to 30 and severe above 30. Our explainer on what your AHI score actually means walks through how those events are counted.
Funding rules diverge just as much. In France both CPAP (PPC, pression positive continue) and a mandibular advancement device (OAM) require an accord préalable completed by the prescribing physician at first prescription and at every renewal.
Continued French reimbursement of PPC is conditional on measured use of at least 3 hours per night with demonstrated efficacy, and renewal of an OAM after two years requires symptom improvement plus at least a 50% reduction in the apnea-hypopnea index. Sleep apnea is not recognised as an ALD in France, unlike MS itself, so a mutuelle is generally needed for full cost coverage.
In the UK, CPAP is provided free on the NHS. NICE NG202 positions CPAP for moderate-to-severe OSAHS or significant symptoms, and mandibular advancement devices for mild-to-moderate OSAHS where suitable. Hypoglossal nerve stimulation and mouth and facial exercises also appear among NHS-listed options. In Germany, statutory insurance generally covers the pathway with a physician referral.
- French moderate OSA starts at IAH 16, while NHS moderate starts at AHI 15.
- French PPC and OAM both need an accord préalable, and PPC reimbursement tracks measured use.
- UK readers should check whether their symptoms trigger a DVLA notification duty.
Getting sleep apnea and multiple sclerosis fatigue untangled with your neurologist
The screening-to-diagnosis gap is documented. In the 2014 Journal of Clinical Sleep Medicine cohort of 195 people with MS, only 21% carried a formal OSA diagnosis while 56% screened positive on STOP-BANG at 3 or more. In that study the population attributable risk suggested 40% of MS fatigue was potentially attributable to elevated OSA risk, and 11% to formally diagnosed OSA.
That gap closes only when someone asks. Here is how to ask well.
1Separate the two words out loud
Say it precisely: "I am not only tired, I fall asleep without meaning to." Fatigue and sleepiness sound alike in a busy clinic, and the second one is what triggers a sleep referral.
2Name the test used in your own system
Ask for a polygraphie ventilatoire in France, a home sleep apnoea test through your GP in the UK, or an ambulante Polygraphie in Germany. A named request is much harder to defer than asking to be checked.
3Ask to be tested before a fatigue prescription
Amantadine and modafinil are commonly used for MS fatigue. Starting a wake-promoting medicine on top of untreated sleep apnea can mask the signal while the breathing problem carries on unaddressed, so request the recording first.
4Prepare an answer for "it is just part of MS"
Reply that you would like to rule out sleep-disordered breathing first, and mention the 21% versus 56% gap. If your neurology clinic cannot arrange testing, your GP or an ENT colleague usually can.
- Only 21% of that MS cohort held a formal OSA diagnosis while 56% screened positive (JCSM, 2014).
- Ask for testing before accepting a wake-promoting drug for fatigue.
- Name the specific first-line test used in your country when you request it.
If your result comes back mild, nasal breathing is the next variable
Test results split the road. Moderate and severe OSA, where much of the MS evidence sits, is CPAP or PPC territory, and the pooled mean AHI in the 2024 Frontiers in Neurology meta-analysis was 20.70 (95% CI 16.31-25.10).
A minority finish testing in the mild band, or with snoring and no significant apnea. There the realistic options are positional therapy, a mandibular advancement device where suitable, and attention to nasal obstruction.
Nasal obstruction and raised nasal resistance deserve their own mention because they are fixable and often overlooked. Poor nasal patency drives snoring, and it is a documented reason people tolerate CPAP badly, which matters twice over in MS. Reduced hand dexterity, tremor and spasticity make mask fitting and strap adjustment genuinely hard, and French reimbursement depends on that measured 3 hours a night.
Back2Sleep is a French company based in Paris that makes a CE-certified Class I soft silicone intranasal stent. It sits inside the nostril to keep the nasal airway open during sleep, needs no prescription, no electricity, no noise and no tubing, and the starter kit contains four sizes so you can find your fit at home. Corticosteroid-related weight gain and reduced activity may also shift snoring risk over time, which is worth reviewing with your team.
- Treatment follows the AHI band, so testing has to come before any purchase.
- Nasal obstruction is a separate, fixable variable that also affects CPAP adherence.
- Device burden is a real MS issue, so ease of handling belongs in the decision.
What to do in the next seven days
Start with observation rather than a purchase. For one week, log whether you doze off unintentionally, whether anyone has heard you stop breathing, and whether a long night helps.
Then book the appointment and use the wording from step one. Testing turns an argument about fatigue into a number your system will act on.
- One week of simple notes is enough to justify a test request.
- Ask by name for the first-line recording used in your country.
- Wait for your AHI band and apnea type before buying anything.
What Back2Sleep Users Say
Frequently Asked Questions
Can sleep apnea be mistaken for MS fatigue?
Yes, and it happens routinely. Both produce daily exhaustion, so clinics often credit it to multiple sclerosis alone. In a 2014 Journal of Clinical Sleep Medicine study of 195 people with MS, only 21% carried a formal obstructive sleep apnea diagnosis while 56% screened positive on STOP-BANG. That gap is why testing matters.
How do I know if my fatigue is from MS or from sleep apnea?
Look for sleepiness rather than tiredness. MS fatigue is an energy failure that persists even after a genuinely good night, while sleep apnea makes you doze off unintentionally when reading or travelling. Snoring, gasping and morning headache point towards breathing. Only an overnight recording can confirm which one you have.
What percentage of people with MS have sleep apnea?
A 2024 meta-analysis in Frontiers in Neurology covering 30 studies and 6,447 patients found obstructive sleep apnea-hypopnea syndrome in 36% when measured by polysomnography, and 1.67 times more often than in controls. Questionnaire estimates were lower, at 26% by STOP-BANG and 30% by the Berlin Questionnaire, so questionnaires under-detect.
Can you have sleep apnea without snoring if you have MS?
Yes. Central sleep apnea is a pause in the brain's breathing signal, so there is no muscular effort and frequently no snoring at all. Brainstem demyelinating lesions are the classic reason central events are discussed in multiple sclerosis. A quiet sleeper with unexplained sleepiness still needs an overnight recording.
Can I ask my neurologist for a sleep study or do I need to see my GP?
Either route can work, so start with whoever you see soonest. Name the test used locally: polygraphie ventilatoire in France, a home sleep apnoea test in the UK, or ambulante Polygraphie in Germany. If your neurology clinic cannot arrange it, your GP, an ENT or a pulmonologist usually can.
Does a low STOP-BANG score rule out sleep apnea in multiple sclerosis?
No. Among 200 people with MS who underwent polysomnography, reported in Multiple Sclerosis Journal in 2021, STOP-BANG at three or more showed 87% sensitivity but only 43% specificity, and its negative predictive value for mild sleep apnea was just 40%. A low score therefore does not clear you.
Will treating sleep apnea improve my MS fatigue?
It may help, although nobody can promise it. In the 2014 Journal of Clinical Sleep Medicine analysis, population attributable risk suggested 40% of MS fatigue was potentially attributable to elevated sleep apnea risk, and 11% to diagnosed apnea. Treating the breathing problem removes one driver; primary MS fatigue may remain.
Ready for quieter nights? Discover the Back2Sleep starter kit and find the right fit for you.
Not sure if you are at risk? Take our sleep risk screening to find out in just a few minutes.
Want to learn how it works? Explore the Back2Sleep nasal stent designed for comfortable, effective relief.